Interventional Treatment of Severe Tricuspid Regurgitation
Early Clinical Experience in a Multicenter, Observational, First-in-Man Study

Alexander Lauten, MD; Hans R. Figulla, MD; Axel Unbehaun, MD; Neil Fam, MD; Joachim Schofer, MD; Torsten Doenst, MD; Joerg Hausleiter, MD; Marcus Franz, MD; Christian Jung, MD, PhD; Henryk Dreger, MD; David Leistner, MD; Brunilda Alushi, MD; Anja Stundl, MD; Ulf Landmesser, MD; Volkmar Falk, MD; Karl Stangl, MD; Michael Laule, MD

Background—Transcatheter caval valve implantation is under evaluation as a treatment option for inoperable patients with severe tricuspid regurgitation (TR). The procedure involves the catheter-based implantation of bioprosthetic valves in the inferior vena cava and superior vena cava to treat symptoms associated with TR. This study is the first to evaluate the feasibility, safety, and efficacy of this interventional concept.

Methods and Results—Twenty-five patients (mean age, 73.9±7.6 years; women, 52.0%) with severe symptomatic TR despite optimal medical treatment deemed unsuitable for surgery were treated with caval valve implantation under a compassionate clinical use program. Technical feasibility defined as procedural success, hemodynamic effect defined as venous pressure reduction, and safety defined as periprocedural adverse events were evaluated, with clinical follow-up at discharge and up to 12 months. The functional impact was evaluated by assessment of New York Heart Association class at the time of hospital discharge. The total number of valves implanted in the caval position was 31. Patients were treated with single (inferior vena cava-only; n=19; 76.0%) or bicaval valve implantation (inferior vena cava+superior vena cava; n=6; 24.0%). Either balloon-expandable valves (Sapien XT/3: n=18; 72.0%) or self-expandable valves (TricValve: n=6; 24.0%; Directflow: n=1; 4.0%) were used. Procedural success was achieved in 96% (n=24). Early and late valve migration requiring surgical intervention occurred in 1 patient each. Thirty-day and in-hospital mortality were 8% (2 of 25) and 16% (4 of 25). Causes of in-hospital mortality included respiratory (n=1) or multiple organ failure (n=3) and were not linked to the procedure. Mean overall survival in the study cohort was 316±453 days (14–1540 days).

Conclusions—Caval valve implantation for the treatment of severe TR and advanced right ventricular failure is associated with a high procedural success rate and seems safe and feasible in an excessive-risk cohort. The study demonstrates hemodynamic efficacy with consistent elimination of TR-associated venous backflow and initial clinical improvement. These results encourage further trials to determine which patients benefit most from this interventional approach. (Circ Cardiovasc Interv. 2018;11:e006061. DOI: 10.1161/CIRCINTERVENTIONS.117.006061.)

Key Words: heart valve prosthesis implantation ■ hemodynamics ■ tricuspid regurgitation ■ tricuspid valve insufficiency ■ venae cavae, superior

Severe tricuspid regurgitation (TR) is a complex condition of the right ventricle (RV) and tricuspid valve apparatus and is frequently associated with symptomatic heart failure and a significant morbidity and mortality.1,2 In these patients, left heart pathologies lead to chronic pressure overload of the RV, eventually causing progressive RV dilatation and functional TR.3-6

In patients with severe TR, medical therapy restricted to diuretics and heart failure medication is frequently ineffective, and surgical repair is associated with a high risk of morbidity and mortality.7-10 Furthermore, neither one of these treatment options has demonstrated beneficial long-term effects. Therefore, multiple innovative interventional treatment concepts to replace or repair tricuspid valve function are currently under investigation.11-18 However, up to date, none of these approaches is established, and there is

See Editorial by O’Neill

Received October 11, 2017; accepted December 18, 2017.
From the Charité – Universitätsmedizin Berlin, Germany (A.L., H.D., D.L., B.A., U.L., K.S., M.L., V.F.); Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Berlin, Germany (A.L., H.D., D.L., B.A., U.L., K.S., M.L., V.F.); Friedrich-Schiller-Universität Jena, Germany (H.R.F., T.D., M.F.); Department of Medicine II, Heart Center Bonn, University Hospital Bonn, Germany (A.S.); German Heart Center Berlin (A.U., V.F.); Division of Cardiology, St. Michaels Hospital, Toronto, Canada (N.F.); Albertinen Heart Center, Hamburg, Germany (J.S.); Medizinische Klinik und Poliklinik I, Ludwig-Maximilians-Universität München, Munich, Germany (J.H.); Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, University Düsseldorf, Germany (C.J.); and Berlin Institute of Health, Germany (U.L.).

The Data Supplement is available at http://circinterventions.ahajournals.org/lookup/suppl/doi:10.1161/CIRCINTERVENTIONS.117.006061/-/DC1. Correspondence to Alexander Lauten, MD, Charité – Universitätsmedizin Berlin, Charité Campus Mitte and Campus Benjamin Franklin, Berlin, Germany. E-mail alexander.lauten@charite.de

© 2018 American Heart Association, Inc.

Circ Cardiovasc Interv is available at http://circinterventions.ahajournals.org DOI: 10.1161/CIRCINTERVENTIONS.117.006061
WHAT IS KNOWN

- Multiple concepts for transcatheter treatment of severe tricuspid regurgitation are currently under investigation.
- Despite the increasing application of these techniques, there is a lack of data on feasibility, safety, and efficacy of these treatment approaches.

WHAT THE STUDY ADDS

- Herein, we summarize the current experience with caval valve implantation in 25 compassionate patients undergoing inferior vena cava-only or bicalval valve implantation using either balloon- or dedicated self-expandable valves.
- As observed in this study, the caval valve implantation technique is feasible and hemodynamically effective and reproducibly results in the reduction of caval backflow in selected patients.
- As observed in the present study, this hemodynamic improvement may potentially translate into clinical improvement.

Implantation Procedure and Devices

Procedural success was defined as successful valve delivery and deployment at the designated landing zone. The procedures were performed under general anesthesia with fluoroscopic and transesophageal echo guidance. Unfractionated heparin was administered to reach an activating clotting time >250 seconds throughout the procedure. The hemodynamic impact was evaluated during the procedure using invasive pressure tracings in the RA and IVC, as well as cardiac output measurements. After the procedure, venous closure was achieved by either the use of percutaneous closure devices or a so-called Z-suture of the skin. Patients were monitored in the intensive or intermediate care unit and discharged home or to a rehabilitation program based on clinical requirements. Anticoagulation was afforded using vitamin K antagonists (eg, phenprocoumon) in all patients.

CAVI Using BEV

The Edwards Sapien BEV have been described previously in detail. Because of the commercial availability of the Edwards Sapien XT and Sapien 3 valves for treatment of aortic stenosis (29-mm Edwards Sapien XT or Sapien 3; Edwards Lifesciences, Irvine, CA), there is a growing experience in the off-label use of these devices for treating severe TR. Although the use of BEV has been commonly limited to the IVC, in selected cases, the long segment of the SVC facilitates BEV implantation using the same implant technique if needed. The anatomy of the cavoatrial junction of the IVC (particularly the large diameter, the inflow of hepatic veins, and the compliance of the venous wall) precludes direct implantation of a BEV and requires the preparation of a landing zone by implanting a self-expandable stent to facilitate valve fixation.

The procedure is performed using fluoroscopy through the right femoral vein. After placement of the 6F sheath, a stiff wire is placed in the SVC and a 16F (for S3) or 20F (for ES XT) sheath advanced below the diaphragm. A self-expandable stent tailored to IVC diameter (eg, 30x80 mm) is implanted in the IVC at the level of the diaphragm and protruding ≈5 mm into the RA. The 29-mm BEV mounted on the delivery system is then deployed inside the stent with the lower part just superior to the confluence of the first hepatic vein (Figure 1). For a bicalval valve implantation (BiCAVI procedure, a self-expanding stent is deployed in the SVC above the RA inflow (to reduce the risk of vessel wall damage and rupture) and the SVC prosthesis implanted in the same manner.

CAVI Using Self-Expandable TricValve

The TricValve (P&F, Vienna, Austria) is designed as a set of 2 self-expandable valves specifically for SVC and IVC implantation in the low pressure circulation. The SVC valve is a belly-shaped tapered device for anchoring in dilated, tapered SVC configuration. The IVC valve is deployed at the level of the diaphragm and protruding into the RA. Both devices are made of bovine pericardium, and the inner part of the atrial stent portion is lined with a polytetrafluorethylene skirt.
For implantation, an Amplatz wire with a long soft J-tip is advanced through the right femoral vein and the RA into the right internal jugular vein. Both devices are loaded into 27F catheters for sheathless implantation. Before SVC valve implantation, a catheter is placed distally in the right pulmonary artery as marker of the IVC–right pulmonary artery crossing. The SVC valve is then deployed with the landing zone of the enlarged midportion of the stent above the right pulmonary artery. The IVC valve is deployed with the upper, skirt-lined segment of the stent protruding into the RA, and the device fully anchored in the IVC. The constrained segment of the stent should be aligned with the caval-atrial junction by careful pullback of the catheter to avoid occlusion of hepatic vein inflow just below the diaphragm. With a safety margin of 5 mm, care was taken to avoid a low or high valve position causing either hepatic vein obstruction or paravalvular regurgitation (Figure 2). All procedures were fluoroscopy and transesophageal echocardiography guided (implantation procedure and echo—Movie in the Data Supplement).

**Statistics**

Continuous data are presented as mean±SD, and categorical variables are depicted as percentages and numbers. Statistical testing was performed with a paired t test for continuous variables if distributed normally, otherwise exact testing was performed. The Wilcoxon signed-rank test was used for categorical variables. A \( P < 0.05 \) was considered statistically significant. Kruskall–Wallis test or \( \chi^2 \) was used for intergroup comparisons. All statistical analyses were performed using the SPSS statistical package, version 23.0 (IBM Corp, New York, NY).
Results

Patients and Baseline Characteristics

Patients (n=25; women, 52%; age, 73.9±7.6 years; EuroScore II, 18.2±12.9; Society of Thoracic Surgeons (STS) mortality score, 14.0±12.7) with massive TR and symptoms of right heart failure were considered for this novel treatment approach under a compassionate clinical use program. The majority of patients had a history of previous cardiac surgery (n=19; 76%), including 6 patients (24%) with ≥2 preceding open heart surgical procedures or aortic replacement because of aortic dissection and 1 patient after heart transplantation. Five (20%) patients had previous transcatheter valve procedures, including transcatheter aortic valve implantation (n=1), transcatheter pulmonary valve (n=2), or MitraClip procedure (n=2).

A significant proportion of patients experienced progressive cancer (n=7; 28%). Thirty-six percent (n=9) had permanent pacers placed positioned in the SVC across the tricuspid annulus. The indication for CAVI was made on decision of local heart teams in nonsurgical patients with persistent and debilitating symptoms of heart failure despite optimal medical therapy. Clinical exclusion criteria included a limited life expectancy <3 month, severely depressed RV function (TAPSE <10 mm), and a systolic pulmonary artery pressure >60 mmHg.

At baseline, 72% (n=18) and 28% (n=7) of patients were in New York Heart Association (NYHA) class IV and III, respectively. Plasma NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels were markedly elevated at 3016 pg/mL (765–5588 pg/mL; Table 1).

Baseline echocardiography showed an impaired ejection fraction <50% in 40% (average ejection fraction, 51.0±15.0%), and an impaired RV function with TAPSE <16 mm was observed in 32% (n=10; average TAPSE, 13.0±1.83 mm). Functional TR was present in 96% (n=24) and structural (rheumatic) TR in 4% (n=1) of patients, respectively. Systolic pulmonary artery pressure was moderately increased at baseline (41.0±13.9 mmHg), and all patients with pulmonary arterial hypertension were in group 2 according to the 2013 Nice classification.

Procedural Results

The total number of valves implanted within this study was 31. Patients were treated with single valve implantation (IVC-only; n=19; 76.0%) or BiCAVI (IVC and SVC; n=6; 24.0%). In these patients, either balloon-expandable valves (Sapien XT or Sapien 3; n=17; 78.3%) or self-expandable valves (TricValve; n=7; 21.7%; Directflow; n=1; 4.0%) were used for either single IVC or BiCAVI. One patient was treated by IVC-only implantation of a direct flow medical valve prosthesis (Direct Flow Medical, Santa Rosa), a nonmetallic device with an inflatable and deflatable support structure (Figure 3). Ninety-six percent of devices were implanted through femoral venous access and 1 implantation (Directflow) via right internal jugular access. When BEV were used, different techniques of IVC landing zone preparation and downsizing were required, such as pre-stenting with ≥1 self-expandable stents (n=16) or surgical banding (n=2), depending on local heart team decision.

Table 1. Patient Demographics and Comorbidities

<table>
<thead>
<tr>
<th>Patient Demographics</th>
<th>Mean±SD and Range or n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean±SD)</td>
<td>73.9±7.6</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>13 (52)</td>
</tr>
<tr>
<td>EuroScore II</td>
<td>18.2±12.9; 5.1–54.2</td>
</tr>
<tr>
<td>STS Score (MVR)*</td>
<td>14.0±12.7; 1.6–42.3</td>
</tr>
<tr>
<td>NYHA III</td>
<td>7 (28)</td>
</tr>
<tr>
<td>NYHA IV</td>
<td>18 (72)</td>
</tr>
<tr>
<td>NT-proBNP</td>
<td>3028 (765–12538)</td>
</tr>
<tr>
<td>Left ventricular ejection fraction (EF, %)</td>
<td>51±15 (15–74)</td>
</tr>
</tbody>
</table>

Intraprocedural and In-Hospital Safety Data

Procedural success (defined as successful delivery of 1 or 2 valves in intended position) was achieved in 92% of cases. There were no intraprocedural deaths. However, in one case, conversion to open heart surgery was required after migration of an SVC prosthesis within minutes after deployment. In another case, an IVC prosthesis migrated from the stent into the RA within the first 30 days. In both cases, the prosthetic valves were surgically recovered from the RV. No other serious events, including stroke, myocardial infarction, pericardial effusion, or vascular complications, occurred (Table 2).

Peri- and Postprocedural Hemodynamics and Echocardiography

In all patients, CAVI resulted in a complete reduction of reverse caval flow. This was confirmed by a significant reduction of the...
IVC v-wave and mean pressure from 31.4±6.4 and 21.7±4.3 mm Hg to 21.1±4.5 mm Hg (P<0.0001) and 17.6±3.3 mm Hg (P=0.01), respectively. In the RA, mean pressure decreased from 21.2±6.0 to 17.6±3.3 mm Hg immediately after implantation, whereas the v-wave acutely increased from 29.5±7.1 to 35.5±13.1 mm Hg (P=0.07; Table 3). Cardiac index, determined either by oximetry or noninvasive echocardiographic measurement, increased nonsignificantly from 2.5±0.7 to 2.8±0.9 L/min per m² (P=0.76).

At baseline, mean TAPSE was 16.5±4.1 and remained unchanged after the procedure (16.5±4.9 mm; P=0.95). In patients with depressed RV function (TAPSE <16 mm) at baseline (n=10), TAPSE improved nonsignificantly from 13.0±1.83 to 13.7±2.95 (P=0.41). RV area and tricuspid annulus remained unchanged (RA area: 64.9±54.4 versus 63.8±50.2 cm²; P=0.94; tricuspid valve annulus: 51.0±6.7 versus 50.4±7.8 mm; P=0.76). Intact valve function was observed in all implanted devices during follow-up (Figure 4).

Postoperative Clinical Course and Clinical Follow-Up

Thirty-day mortality was 12% (n=3; Table 2). These patients died from progressive multiorgan failure and septic complications 6, 14, and 24 days after the intervention. In-hospital mortality was 24% (n=6). Two patients developed pneumonia and died from respiratory failure day 34 and day 41 after implantation and 1 patient died from multiple organ failure 45 days after implantation.

Mean follow-up time after the procedure was 316±453 days (14–1540 days) after CAVI. In all patients discharged alive from hospital (n=19), transthoracic echocardiography obtained during follow-up confirmed appropriate function of all implanted devices. Longest follow-up of 51 month is available for a BiCAVI patient with documented intact valve function. Before the procedure, 72% of patients were in NYHA class IV. In patients discharged from hospital (n=19), symptoms improved in 84.2% (n=16) by ≥1 NYHA class. At the time of discharge, 9 patients remained in NYHA class III or IV (47.3%) and 52.7% improved to NYHA class I or II (Figure 5). Plasma NT-proBNP levels were markedly elevated at baseline and increased nonsignificantly within 30 days after the procedure (NT-proBNP: 3028 pg/mL [765–12 538 pg/mL] versus 10711 [6510–23 054] mL; P=0.015).

**Table 2. Procedural, Safety, and In-Hospital Data**

<table>
<thead>
<tr>
<th></th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>25 (100)</td>
</tr>
<tr>
<td>No. of valves implanted</td>
<td>31 (100)</td>
</tr>
<tr>
<td>IVC-only (devices)</td>
<td>19 (61.3)</td>
</tr>
<tr>
<td>ES XT or ES 3</td>
<td>16</td>
</tr>
<tr>
<td>TricValve</td>
<td>2</td>
</tr>
<tr>
<td>Directflow Medical</td>
<td>1</td>
</tr>
<tr>
<td>BiCAVI (devices)</td>
<td>12 (38.7)</td>
</tr>
<tr>
<td>ES XT</td>
<td>2</td>
</tr>
<tr>
<td>TricValve</td>
<td>10</td>
</tr>
<tr>
<td>Immediate procedural success</td>
<td>23/25 (92)</td>
</tr>
<tr>
<td>Device embolization</td>
<td>2/25 (8)</td>
</tr>
<tr>
<td>Conversion to surgery</td>
<td>1/25 (4)</td>
</tr>
<tr>
<td>Vascular complications</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Bleeding complications other than access site</td>
<td>3/25 (12)</td>
</tr>
<tr>
<td>New permanent pacemaker</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Stroke</td>
<td>0/25 (0)</td>
</tr>
<tr>
<td>New onset renal failure (requiring dialysis)</td>
<td>0/14 (0)</td>
</tr>
<tr>
<td>NYHA improvement</td>
<td>13/18 (72)</td>
</tr>
</tbody>
</table>

**Mortality**

<table>
<thead>
<tr>
<th></th>
<th>12 mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 d</td>
<td>3/25 (12%)</td>
</tr>
<tr>
<td>In-hospital</td>
<td>6/25 (24%)</td>
</tr>
<tr>
<td>Mean long-term follow-up, d</td>
<td>316±453; (6–1540)</td>
</tr>
</tbody>
</table>

BiCAVI indicates bicaval valve implantation; and IVC, inferior vena cava.

*Twelve-month follow-up complete for n=22 patients only. Three patients were implanted <12 months.*
Because medical therapy is often ineffective for long-term treatment of symptoms associated with severe TR, interventional treatment approaches are gaining increasing attention, and several catheter-based approaches and dedicated devices are currently under investigation.\textsuperscript{13,14} These interventional strategies are frequently adopted from the mitral space, including concepts, such as leaflet approximation, coaptation enhancement, and direct and indirect annuloplasty.\textsuperscript{11,17,25–28} All of these concepts and devices are in early stages of clinical development with experience limited to patient series and follow-up of weeks to months at best. In this developing and innovative field, the optimal concept remains a matter of debate.

Herein, we describe the currently used techniques and devices used for CAVI and summarize the available evidence in the largest study cohort treated with this concept. The procedure was first performed in patients in 2010 and was one of the first interventional strategies to be applied for TR treatment.\textsuperscript{21} Since then, multiple institutions have adopted this procedure for compassionate use cases of patients with late-stage TR and associated RV failure. In these patients, TR is most frequently functional in nature and associated with RV dilatation and dysfunction. Structural defects are rare as can be observed by the distribution of TR pathogenesis in the present study.

The CAVI approach primarily aims to resolve backflow into the caval veins and treat associated symptoms of heart failure. In the pathological cascade of TR, caval backflow occurs at an advanced stage of disease, frequently associated with RV and venous dilatation, impaired RV function, and atrial fibrillation. This fact together with the novelty of the approach and the limited availability of devices resulted in the selection of advanced stage patients with severe and frequently life-limiting concomitant comorbidities, frequently undergoing a last-resort treatment approach. In this study, the STS score was 14.0±12.7, 76% of the patients had previously undergone open heart surgery, 44% (n=11) were in end-stage renal failure, and 28% (n=7) experienced concomitant cancer disease. Despite this unfavorable risk profile, immediate procedural success was 96% (n=24), demonstrating the feasibility and safety of the procedure. Conversion to surgery was required in one case after immediate SVC valve migration. A second patient underwent surgery because of IVC valve migration 10 days after implantation. The implantation procedure was associated with no intra-procedural mortality.

Of note, 36% of patients had a permanent pacemaker in place, which is considered as potential contraindication for other TR-dedicated devices. In the current study, the presence of pacemaker or implantable cardioverter defibrillator leads in the SVC did neither impact the CAVI procedure nor did we observe an effect of the implanted devices on pacemaker or implantable cardioverter defibrillator function.

Because of the limited availability of dedicated devices, balloon-expandable transcatheter aortic valve implantation valves are currently most frequently used for CAVI. In the present study, the use of these devices proved feasible and was hemodynamically effective. However, their use is associated with anatomic limitations with regard to anchoring and sizing. As can be observed by the treatment strategy in the present study, BEV were almost exclusively used for IVC implantation. A BEV implantation into the SVC was performed in only one patient after SVC who presented with a lean, nontapered SVC configuration (Figure 1).

In patients with chronic right heart failure and severe TR, the central segment of the SVC is atrialized and frequently develops tapered dilatation, requiring an anchoring strategy in the upper, nondilated part of the superior vein segment—as afforded by the TricValve stent frame. Furthermore, current generations of BEV are available up to 29 mm only and thus frequently undersized for patients with severely dilated caval veins. The use of BEV for CAVI is, therefore, clearly restricted to the IVC-only and should be performed in the SVC-only in after careful anatomic evaluation.

In this excessive-risk study population, 30-day mortality and in-hospital mortality were 8% and 24%, respectively, with patients dying from noncardiovascular causes despite successful treatment of TR.

The study further confirms the hemodynamic and clinical effect of the procedure in patients with severe TR and central
venous congestion. Major concerns associated with CAVI include the ventricularization of RA pressure, as well as the persistence of atrial and ventricular volume overload, potentially promoting RV failure and atrial fibrillation. In the present limited human experience, no such deleterious effects were observed. In all patients, the CAVI procedure successfully resolved hemodynamic backflow with a significant reduction of mean pressure in the IVC and the RA from 21.7±4.3 and 21.2±6.0 mm Hg to 17.6±3.3 mm Hg (P=0.01) and 17.0±3.9 mm Hg (P=0.02), respectively. Despite the immediate increase of the v-wave in the RA from 29.5±7 mm Hg before the procedure to 35.5±13.1 mm Hg (P=0.07) after the procedure, echo follow-up suggests neither an increase of RA size (64.9±54.4 versus 63.8±50.2 cm²; P=0.94) nor deterioration of RF function (TAPSE 16.5±4.1 versus 16.5±4.9 mm; P=0.95). These observations are in line with earlier reports.

In patients discharged from hospital, CAVI was associated with a symptomatic improvement in 84.2% of patients, with 50.2% of patients improving to NYHA class I or II. Although NT-proBNP values show an upward trend after CAVI, this parameter is likely of limited diagnostic value because of the ventricularization of the RA hemodynamics and the exposition of the RV to a higher afterload after CAVI. Because of the limited number of patients in this study, it is yet unanswered whether bicaval versus single valve implantation has different effects on hemodynamic or clinical outcome. However, this question will be subject of further trials. In the present experience, BiCAVI was preformed whenever possible from an anatomic perspective with the available devices.

Although hemodynamically effective, CAVI is in contrast to other interventional procedures because it aims to treat an advanced disease state of central venous regurgitation. In a recent study by Nickenig et al,11 tricuspid edge-to-edge repair using the MitraClip device proved effective to reduce TR severity and improve associated symptoms of heart failure. Although the edge-to-edge technique is an orthotopic treatment concept aiming to restore tricuspid valve function, the technique reduced but did not resolve TR to trace or zero in the majority of patients, which was nevertheless associated with symptomatic improvement.11 The study by Nickenig et al11 included nonsurgical patients as well; however, the patient population presented a more favorable risk profile with less comorbidities. The difference in risk profile is confirmed by an STS score of 4.7±4.6 in the study by Nickenig et al11 versus an STS of 14.0±12.7 in the present study. This finding supports an earlier general observation that patients with severe TR resemble a heterogenic cohort with a wide span of comorbidities, risk profiles, and anatomic specification essentially necessitating a stratified approach for interventional TR treatment.

Limitations

Our exploratory study presents observational data on feasibility of CAVI and summarizes the current experience with this treatment approach. The number of patients is limited, patients were not randomized, and data were acquired without core laboratory adjudication. Because of its exclusive compassionate use, the present clinical experience is currently...
Figure 5. Boxplot diagrams of echocardiographic and hemodynamic changes before vs after implantation. A–C, Tricuspid annulus diameter, tricuspid annular plane systolic excursion, and right atrial (RA) area in transthoracic echo before caval valve implantation (CAVI) and before discharge. D–F, Cardiac index, mean pressure, and v-wave in the inferior vena cava (IVC) and in the RA before vs immediately after CAVI. °Extreme values. *Statistical outlier. TAPSE indicates tricuspid annular plane systolic extension.
limited to the most severely ill subgroup of patients with limited clinical follow-up. It, therefore, remains unclear whether the presented treatment modality is able to induce a sustained clinical improvement or improve patient prognosis.

**Conclusions**

Treatment of severe TR and caval backflow with the CAVI technique is feasible and hemodynamically effective. The associated hemodynamic improvement may potentially translate into clinical improvement as observed in the present study. However, further studies, including randomized trials, are necessary to determine which patients benefit most from interventional treatment and to adjust criteria for clinical and anatomic patient selection for different subgroups.

**Disclosures**

Dr Lauten is a consultant to P&F TrivCable and receives research support from Edwards Lifesciences. Dr Figulla is a consultant to P&F TrivCable. Drs Stangl and Laule received proctoring fees and research support from Edwards Lifesciences. The other authors report no conflicts.

**References**

Interventional Treatment of Severe Tricuspid Regurgitation: Early Clinical Experience in a Multicenter, Observational, First-in-Man Study


Circ Cardiovasc Interv. 2018;11:
doi: 10.1161/CIRCINTERVENTIONS.117.006061
Circulation: Cardiovascular Interventions is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2018 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-7640. Online ISSN: 1941-7632

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circinterventions.ahajournals.org/content/11/2/e006061

Data Supplement (unedited) at:
http://circinterventions.ahajournals.org/content/suppl/2018/02/15/CIRCINTERVENTIONS.117.006061.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Interventions can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Interventions is online at:
http://circinterventions.ahajournals.org//subscriptions/
Online supplement – Video 1:

Implantation procedure guided by fluoroscopy and transesophageal echo.